<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30045313</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>08</Month>            <Day>02</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1536-5964</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>97</Volume>                    <Issue>30</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Jul</Month>                    </PubDate>                </JournalIssue>                <Title>Medicine</Title>                <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>            </Journal>            <ArticleTitle>Lymphovascular invasion can be better than pathologic complete response to predict prognosis in breast cancer treated with neoadjuvant chemotherapy.</ArticleTitle>            <Pagination>                <MedlinePgn>e11647</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000011647</ELocationID>            <Abstract>                <AbstractText>Lymphovascular invasion (LVI) has been a predictor of worse survival outcomes in breast cancer. However, the role of LVI compared than pathologic complete response (pCR) following neoadjuvant chemotherapy (NAC) remains unclear. The aim of this study was to examine the association between LVI and survival outcomes and clinicopathological features in patients with breast cancer treated with NAC. We retrospectively analyzed 187 patients with breast cancer treated with NAC and surgery between 2005 and 2013 in our institution. Kaplan-Meier analyses were used to assess recurrence-free survival (RFS) and overall survival (OS). Median follow-up was 57.9 months. Mastectomy (vs breast conserving surgery [BCS]; hazard ratio [HR], 1.791; 95% confidence interval [CI], 1.022-3.139; P = .042), ypN1-3 stage (vs ypN0 stage; HR, 2.561; 95% CI, 1.247-5.261; P = .010), and LVI (vs no LVI; HR, 2.041; 95% CI, 1.170-3.562; P = .012) were associated with worse RFS. Mastectomy (vs BCS; HR, 2.768; 95% CI, 1.173-6.535; P = .020), LVI (vs no LVI; HR, 3.474; 95% CI, 1.646-7.332, P = .001), and human epidermal growth factor receptor 2 overexpression type (vs luminal A type; HR, 11.360; 95% CI, 1.501-85.972; P = .019) were associated with worse OS. Patients with LVI and hormone receptor-negative cancer had the worst RFS (P &lt; .001) and OS (P &lt; .001). LVI more than pCR in surgical breast cancer specimens obtained after NAC was a significant independent prognostic factor. Patients with hormonal receptor-negative cancer and LVI had unfavorable survival outcomes. We suggest that patients with hormone receptor-negative cancer and LVI should receive short-term follow-up and appropriate management.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Ryu</LastName>                    <ForeName>Young Jae</ForeName>                    <Initials>YJ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Chonnam National University Hwasun Hospital and Medical School, Jeollanam-do, South Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kang</LastName>                    <ForeName>Shin Jae</ForeName>                    <Initials>SJ</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Cho</LastName>                    <ForeName>Jin Seong</ForeName>                    <Initials>JS</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Yoon</LastName>                    <ForeName>Jung Han</ForeName>                    <Initials>JH</Initials>                </Author>                <Author ValidYN="Y">                    <LastName>Park</LastName>                    <ForeName>Min Ho</ForeName>                    <Initials>MH</Initials>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D064888">Observational Study</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Medicine (Baltimore)</MedlineTA>            <NlmUniqueID>2985248R</NlmUniqueID>            <ISSNLinking>0025-7974</ISSNLinking>        </MedlineJournalInfo>        <CitationSubset>AIM</CitationSubset>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2005 Feb 2;97(3):188-94</RefSource>                <PMID Version="1">15687361</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2014 Dec 1;32(34):3883-91</RefSource>                <PMID Version="1">25349292</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast J. 2009 Mar-Apr;15(2):146-54</RefSource>                <PMID Version="1">19292800</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Surg Oncol. 2011 Jan;37(1):18-24</RefSource>                <PMID Version="1">21093206</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2010 Jan 30;375(9712):377-84</RefSource>                <PMID Version="1">20113825</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Surg Oncol. 2012 Jan;19(1):253-8</RefSource>                <PMID Version="1">21725686</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2006 May 1;24(13):2019-27</RefSource>                <PMID Version="1">16606972</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Pathol Lab Med. 2014 Aug;138(8):1048-52</RefSource>                <PMID Version="1">25076293</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Sci. 2009 Oct;100(10):1823-33</RefSource>                <PMID Version="1">19604245</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 1998 Aug;16(8):2672-85</RefSource>                <PMID Version="1">9704717</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Cancer. 2006 Feb;42(3):357-62</RefSource>                <PMID Version="1">16377180</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Breast Cancer. 2014 Dec;17(4):376-85</RefSource>                <PMID Version="1">25548587</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2009 May 20;101(10):729-35</RefSource>                <PMID Version="1">19436035</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncologist. 2006 Jun;11(6):574-89</RefSource>                <PMID Version="1">16794237</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2004 Dec 13;91(12):2012-7</RefSource>                <PMID Version="1">15558072</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer. 2011 Oct;18(4):309-13</RefSource>                <PMID Version="1">20574730</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2007 Oct 15;110(8):1687-96</RefSource>                <PMID Version="1">17722109</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2007 Jul 1;25(19):2650-5</RefSource>                <PMID Version="1">17602071</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2012 May 20;30(15):1796-804</RefSource>                <PMID Version="1">22508812</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2005 Dec 20;23(36):9304-11</RefSource>                <PMID Version="1">16361629</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Breast Cancer. 2002 Jan;2(4):294-8</RefSource>                <PMID Version="1">11899361</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Arch Pathol Lab Med. 2010 Jun;134(6):907-22</RefSource>                <PMID Version="1">20524868</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2005 Sep 1;23(25):5983-92</RefSource>                <PMID Version="1">16087943</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Breast Cancer. 2011 Sep;14(3):198-203</RefSource>                <PMID Version="1">22031801</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2016 Jun;157(3):555-64</RefSource>                <PMID Version="1">27225388</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Asia Pac J Clin Oncol. 2017 Aug;13(4):329-336</RefSource>                <PMID Version="1">27869361</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2008 Feb 10;26(5):778-85</RefSource>                <PMID Version="1">18258986</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast J. 2012 Sep;18(5):415-9</RefSource>                <PMID Version="1">22776042</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2013 Nov 1;31(31):3997-4013</RefSource>                <PMID Version="1">24101045</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer. 2014 Jan;21(1):86-95</RefSource>                <PMID Version="1">22477265</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>                <QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017024" MajorTopicYN="Y">Chemotherapy, Adjuvant</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008198" MajorTopicYN="N">Lymph Nodes</DescriptorName>                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008207" MajorTopicYN="N">Lymphatic Metastasis</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008408" MajorTopicYN="N">Mastectomy</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015412" MajorTopicYN="N">Mastectomy, Segmental</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D020360" MajorTopicYN="Y">Neoadjuvant Therapy</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009361" MajorTopicYN="N">Neoplasm Invasiveness</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>7</Month>                <Day>26</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>7</Month>                <Day>26</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>3</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30045313</ArticleId>            <ArticleId IdType="doi">10.1097/MD.0000000000011647</ArticleId>            <ArticleId IdType="pii">00005792-201807270-00066</ArticleId>            <ArticleId IdType="pmc">PMC6078671</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>